NASDAQ:SBRA - Sabra Health Care REIT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $17.54
  • Forecasted Upside: 0.91 %
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 7 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$17.38
▲ +0.1 (0.58%)
1 month | 3 months | 12 months
Get New Sabra Health Care REIT Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBRA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$17.54
▲ +0.91% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Sabra Health Care REIT in the last 3 months. The average price target is $17.54, with a high forecast of $25.00 and a low forecast of $14.00. The average price target represents a 0.91% upside from the last price of $17.38.
Hold
The current consensus among 12 contributing investment analysts is to hold stock in Sabra Health Care REIT. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 1 sell ratings
8/4/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 1 sell ratings
11/2/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 1 sell ratings
1/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2021MizuhoDowngradeBuy ➝ Neutral$18.00Low
i
1/13/2021Jefferies Financial GroupUpgradeHold ➝ Buy$17.00 ➝ $20.00Low
i
1/7/2021BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$19.00Low
i
12/15/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$14.00 ➝ $17.00Medium
i
12/15/2020Smith Barney CitigroupBoost Price Target$14.00 ➝ $17.00Medium
i
12/3/2020JMP SecuritiesUpgradeMarket Perform ➝ Outperform$24.00Medium
i
10/2/2020MizuhoBoost Price TargetBuy$14.00 ➝ $16.00High
i
9/1/2020Stifel NicolausReiterated RatingHold$15.00High
i
7/2/2020CitigroupBoost Price TargetNeutral$10.00 ➝ $14.00Low
i
6/23/2020ScotiabankUpgradeSector Underperform ➝ Sector Perform$12.00 ➝ $15.00Medium
i
6/22/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$13.00 ➝ $14.00Low
i
6/8/2020JMP SecuritiesInitiated CoverageMarket PerformLow
i
5/18/2020Berenberg BankUpgradeHold ➝ Buy$15.00High
i
4/23/2020SunTrust BanksReiterated RatingHold$15.00Medium
i
4/7/2020CitigroupLower Price TargetNeutral$20.00 ➝ $10.00High
i
Rating by Nicholas Joseph at Citigroup Inc.
3/26/2020Wells Fargo & CompanyLower Price TargetEqual Weight$22.00 ➝ $10.50Medium
i
3/23/2020Bank of AmericaDowngradeNeutral ➝ UnderperformMedium
i
2/26/2020MizuhoUpgradeNeutral ➝ Buy$22.00Low
i
2/6/2020BarclaysLower Price TargetOverweight$26.00 ➝ $25.00Low
i
2/5/2020Berenberg BankInitiated CoverageHold$22.00Medium
i
12/19/2019MizuhoInitiated CoverageNeutral$22.00Medium
i
12/18/2019CitigroupUpgradeSell ➝ Neutral$20.00High
i
10/14/2019Bank of AmericaInitiated CoverageNeutralLow
i
9/27/2019JMP SecuritiesBoost Price TargetMarket Outperform$22.00 ➝ $23.00Low
i
9/23/2019CitigroupDowngradeNeutral ➝ Sell$18.00 ➝ $20.00Low
i
9/3/2019BarclaysInitiated CoverageOverweight$24.00High
i
2/26/2019BMO Capital MarketsDowngradeMarket Perform ➝ UnderperformMedium
i
1/14/2019BMO Capital MarketsReiterated RatingHold$17.00Medium
i
12/18/2018SunTrust BanksDowngradeBuy ➝ HoldMedium
i
11/20/2018CitigroupSet Price TargetHold$18.00Low
i
Rating by Michael Bilerman at Citigroup Inc.
11/16/2018Bank of AmericaDowngradeNeutral ➝ Underperform$23.00 ➝ $21.00Medium
i
11/16/2018Raymond JamesDowngradeOutperform ➝ Market PerformMedium
i
Rating by Jonathan Hughes at Raymond James
11/13/2018MizuhoDowngradeBuy ➝ Neutral$21.00Medium
i
9/18/2018BMO Capital MarketsInitiated CoverageMarket Perform$24.00Medium
i
8/17/2018Raymond JamesBoost Price TargetOutperform ➝ Buy$22.00 ➝ $24.00Medium
i
Rating by Jonathan Hughes at Raymond James
8/13/2018MizuhoReiterated RatingBuy$26.00Low
i
Rating by Richard Anderson at Mizuho
7/18/2018Jefferies Financial GroupReiterated Rating$21.91$22.00Low
i
6/11/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Market Outperform$21.00 ➝ $22.00Low
i
6/4/2018Cantor FitzgeraldReiterated RatingBuy$25.00Medium
i
6/1/2018Raymond JamesUpgradeOutperformLow
i
Rating by Jonathan Hughes at Raymond James
5/21/2018Raymond JamesUpgradeMarket Perform ➝ OutperformHigh
i
Rating by Jonathan Hughes at Raymond James
5/14/2018JMP SecuritiesBoost Price TargetOutperform ➝ Outperform$19.00 ➝ $21.00Low
i
5/9/2018Cantor FitzgeraldReiterated RatingBuy$25.00High
i
3/26/2018Bank of AmericaUpgradeUnderperform ➝ Neutral$20.00Medium
i
3/20/2018Wells Fargo & CompanyLower Price TargetMarket Perform ➝ Market Perform$24.00 ➝ $19.00Medium
i
3/14/2018MizuhoUpgradeNeutral ➝ Buy$24.00Low
i
Rating by Richard Anderson at Mizuho
2/23/2018MizuhoSet Price TargetHold$18.00Low
i
Rating by Richard Anderson at Mizuho
2/22/2018Stifel NicolausReiterated RatingHold ➝ Hold$22.00 ➝ $21.00Medium
i
1/22/2018SunTrust BanksSet Price TargetBuy$22.00Low
i
Rating by Eric Fleming at SunTrust Banks, Inc.
12/21/2017Jefferies Financial GroupReiterated RatingBuy ➝ HoldLow
i
12/13/2017Raymond JamesReiterated RatingHoldMedium
i
Rating by Jonathan Hughes at Raymond James
11/3/2017SunTrust BanksReiterated RatingBuy$25.00N/A
i
11/3/2017Stifel NicolausReiterated RatingHold$22.00N/A
i
10/9/2017SunTrust BanksReiterated RatingBuy$30.00N/A
i
10/4/2017MizuhoReiterated RatingHold$23.00Low
i
9/28/2017Cantor FitzgeraldReiterated RatingBuy$30.00Low
i
9/27/2017Jefferies Financial GroupReiterated RatingBuy$25.00 ➝ $24.00Low
i
9/25/2017Capital One FinancialInitiated CoverageEqual Weight$24.00Low
i
Rating by D. Bernstein at Capital One Financial Co.
9/11/2017MizuhoUpgradeUnderperform ➝ Neutral$23.00 ➝ $24.00Medium
i
9/8/2017Bank of AmericaBoost Price TargetUnderperform$21.00 ➝ $22.00Low
i
9/8/2017Cantor FitzgeraldReiterated RatingBuy$30.00Medium
i
9/5/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$23.00Low
i
8/15/2017Jefferies Financial GroupUpgradeHold ➝ Buy$25.00Medium
i
7/28/2017Stifel NicolausReiterated RatingHold$26.00Medium
i
7/10/2017MizuhoDowngradeNeutral ➝ Underperform$25.00 ➝ $23.00Low
i
7/9/2017Jefferies Financial GroupReiterated RatingHold$28.00 ➝ $25.00Low
i
6/28/2017MizuhoReiterated RatingNeutralLow
i
5/12/2017Jefferies Financial GroupReiterated RatingHold$28.00Low
i
5/9/2017Canaccord GenuityReiterated RatingHold$26.00Low
i
5/8/2017Cantor FitzgeraldReiterated RatingBuy$30.00High
i
2/28/2017Cantor FitzgeraldBoost Price TargetOverweight$25.00 ➝ $30.00N/A
i
2/27/2017Stifel NicolausBoost Price TargetHold$24.00 ➝ $26.00N/A
i
2/27/2017MizuhoReiterated RatingNeutral ➝ Neutral$22.00 ➝ $28.00N/A
i
1/31/2017Jefferies Financial GroupReiterated RatingHold$25.00N/A
i
12/28/2016JMP SecuritiesReiterated RatingMarket PerformN/A
i
10/23/2016Jefferies Financial GroupReiterated RatingHold$25.00N/A
i
10/10/2016MizuhoReiterated RatingNeutral$23.00N/A
i
Rating by Richard Anderson at Mizuho
9/9/2016JMP SecuritiesReiterated RatingHoldN/A
i
9/9/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Joseph France at Cantor Fitzgerald
8/25/2016BTIG ResearchInitiated CoverageNeutralN/A
i
8/19/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Joseph France at Cantor Fitzgerald
8/17/2016CitigroupBoost Price TargetNeutral$22.00 ➝ $24.00N/A
i
7/25/2016Bank of AmericaDowngradeNeutral ➝ UnderperformN/A
i
7/7/2016CitigroupLower Price TargetNeutral$24.00 ➝ $22.00N/A
i
6/23/2016Cantor FitzgeraldInitiated CoverageBuy$28.00N/A
i
Rating by Joseph France at Cantor Fitzgerald
6/1/2016SunTrust BanksUpgradeNeutral ➝ Buy$25.00N/A
i
5/31/2016Canaccord GenuityReiterated RatingHold$23.00N/A
i
Rating by Paul Morgan at Canaccord Genuity
5/19/2016MizuhoDowngradeBuy ➝ Neutral$25.00 ➝ $20.00N/A
i
5/2/2016Canaccord GenuityReiterated RatingHoldN/A
i
Rating by Paul Morgan at Canaccord Genuity
4/12/2016Raymond JamesDowngradeOutperform ➝ Market PerformN/A
i
4/7/2016Jefferies Financial GroupBoost Price TargetHold$21.00N/A
i
4/6/2016Canaccord GenuityReiterated RatingHoldN/A
i
Rating by Paul Morgan at Canaccord Genuity
2/23/2016BarclaysLower Price TargetOverweight$23.00 ➝ $21.00N/A
i
2/23/2016(FBRC)Reiterated RatingOutperform$26.00 ➝ $24.00N/A
i
Rating by Daniel Altscher at (FBRC)
2/14/2016(FBRC)Reiterated RatingOutperform$26.00N/A
i
Rating by Daniel Altscher at (FBRC)
1/29/2016(FBRC)Reiterated RatingOutperform$26.00N/A
i
Rating by Daniel Altscher at (FBRC)
(Data available from 1/26/2016 forward)
Sabra Health Care REIT logo
As of September 30, 2020, Sabra's investment portfolio included 425 real estate properties held for investment (consisting of (i) 287 Skilled Nursing/Transitional Care facilities, (ii) 64 Senior Housing communities (ÂSenior Housing - LeasedÂ), (iii) 47 Senior Housing communities operated by third-party property managers pursuant to property management agreements (ÂSenior Housing - ManagedÂ) and (iv) 27 Specialty Hospitals and Other facilities), one asset held for sale, one investment in a direct financing lease, 19 investments in loans receivable (consisting of (i) one mortgage loan, (ii) one construction loan and (iii) 17 other loans), six preferred equity investments and one investment in an unconsolidated joint venture that owns 158 Senior Housing - Managed communities. As of September 30, 2020, Sabra's real estate properties held for investment included 42,378 beds/units and its unconsolidated joint venture included 7,056 beds/units, spread across the United States and Canada.
Read More

Today's Range

Now: $17.38
$16.90
$17.47

50 Day Range

MA: $17.44
$16.84
$17.97

52 Week Range

Now: $17.38
$5.55
$22.55

Volume

1,511,273 shs

Average Volume

1,319,712 shs

Market Capitalization

$3.60 billion

P/E Ratio

25.19

Dividend Yield

6.94%

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Sabra Health Care REIT?

The following Wall Street research analysts have issued stock ratings on Sabra Health Care REIT in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Jefferies Financial Group Inc., JMP Securities, Mizuho, Scotiabank, Smith Barney Citigroup, Stifel Nicolaus, SunTrust Banks, Inc., TheStreet, Wells Fargo & Company, and Zacks Investment Research.

What is the current price target for Sabra Health Care REIT?

13 Wall Street analysts have set twelve-month price targets for Sabra Health Care REIT in the last year. Their average twelve-month price target is $17.54, suggesting a possible upside of 1.1%. Barclays PLC has the highest price target set, predicting SBRA will reach $25.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $14.00 for Sabra Health Care REIT in the next year.

What is the current consensus analyst rating for Sabra Health Care REIT?

Sabra Health Care REIT currently has 1 sell rating, 7 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SBRA, but not buy more shares or sell existing shares.

What other companies compete with Sabra Health Care REIT?

How do I contact Sabra Health Care REIT's investor relations team?

Sabra Health Care REIT's physical mailing address is 18500 VON KARMAN AVENUE SUITE 550, IRVINE CA, 92612. The real estate investment trust's listed phone number is 888-393-8248 and its investor relations email address is [email protected] The official website for Sabra Health Care REIT is www.sabrahealth.com.